OBJECTIVE: Dual antiplatelet therapy with ticagrelor and aspirin is associated with an increased risk of perioperative bleeding complications. Current guidelines recommend therefore discontinuation of ticagrelor 5 days before surgery to allow sufficient recovery of platelet function. It is not known how the time to recovery varies between individual patients after discontinuation of ticagrelor.
INTRODUCTION
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 -inhibitor (e.g. clopidogrel or ticagrelor) reduces thromboembolic events in patients with acute coronary syndrome (ACS) [1, 2] , but it increases the risk of perioperative bleeding complications if there is a need for acute surgery [3] . Current guidelines recommend discontinuation of the P2Y 12 -inhibitor prior to major surgery, to reduce the risk of bleeding [4, 5] . The recommendations are based on the pharmacological properties of the P2Y 12 -inhibitors [6] and on recovery of platelet function in patients with stable angina [7] . Guidelines recommend withdrawal 5 days before surgery for both clopidogrel and ticagrelor despite the fact that ticagrelor has different pharmacodynamic and pharmacokinetic profiles than clopidogrel. Ticagrelor is a direct-acting, reversible antagonist whereas clopidogrel is a prodrug with irreversible binding, translating into more consistent platelet inhibition and faster onset and offset of the inhibitory effect of ticagrelor [6] . An individual variation in time to recovery of platelet function after withdrawal of P2Y 12 -inhibitors in ACS patients has been reported for clopidogrel and prasugrel before [8, 9] but not for ticagrelor.
Current guidelines recommend that treatment with platelet concentrate should be considered in case of ongoing bleeding, also in patients with ongoing or recently stopped DAPT [4] . The effect of platelet transfusion on adenosine diphosphate (ADP)-dependent platelet aggregation is limited in patients with ongoing treatment with P2Y 12 -inhibitors, especially ticagrelor [10] [11] [12] [13] . It is not known, however, whether platelet transfusion becomes more effective when the effect of the inhibitor wears off, for example after withdrawal of the P2Y 12 -inhibitor before surgery. A shorter discontinuation period before surgery might be acceptable if the effect of the P2Y 12 -inhibitor when necessary could be counteracted with platelet transfusion.
The first aim of this study was to describe the recovery of ADP-dependent platelet aggregation after withdrawal of ticagrelor in ACS patients awaiting urgent coronary artery bypass grafting (CABG), both at group level and in individual patients. The second aim was to predict the efficacy of in vivo platelet transfusion at consecutive timepoints after withdrawal of ticagrelor before CABG, by assessing the efficacy of ex vivo platelet supplementation on platelet aggregation. We therefore designed a prospective observational study in two parts (from now on referred to as Studies I and II).
METHODS

Patients
In Study I, we included 25 patients (mean age 67.9 ±9.1 years, two women) from two coronary care units at our institution from January 2013 to June 2015. Eligible for inclusion were patients >18 years of age with ongoing ticagrelor treatment intended for discontinuation 5 days prior to CABG. Exclusion criteria were known bleeding disorder and liver and kidney disease. All patients were hospitalized with ACS (STEMI, NSTEMI or unstable angina pectoris) and accepted for urgent CABG (within 7 days). All study patients were treated according to current guidelines [4, 5] regarding preoperative medication and discontinuation thereof, and were initially treated with aspirin and ticagrelor. Upon acceptance for CABG, ticagrelor was discontinued and the patient was informed about the study and was included after giving informed written consent. One included patient declined further blood sampling after 24 h. Due to logistic reasons, we were not able to assess platelet function at all timepoints in all patients, see below. Aspirin was not discontinued. No patients were treated with GPIIb/IIIa-inhibitors or direct thrombin inhibitors such as bivalirudin. Study II included a subset of patients from Study I, patients from one of the coronary care units (n = 15, mean age 67.7 ±8.3 years, two women). The study was approved by the regional research ethics committee and was performed in accordance with the 1975 Declaration of Helsinki. Patient characteristics are summarized in Table 1 .
Study I
Venous blood samples were collected by a trained nurse 12 h (n = 16), 24 h (n = 24), 48 h (n = 25), 72 h (n = 24) and 96 h (n = 20) after ticagrelor discontinuation. The samples were drawn from a peripheral vein and collected in a 3-ml test tube with 0.15 mg l -1 hirudin for anticoagulation. The blood samples were analysed with multielectrode aggregometry (MEA; Multiplate V R ; Roche Diagnostics, Basel, Switzerland), as previously described [14] . MEA gives aggregability in arbitrary aggregation units (U). As activators, we used ADP (final concentration 6.5 lmol l ).
The ADP-test with prostaglandin detects P2Y 12 -dependent aggregation with a high degree of sensitivity. The AA-test assesses cyclooxygenase-dependent (i.e. aspirin-sensitive) platelet aggregation. The TRAP-test detects protease activated receptor-1-dependent platelet aggregation and is commonly used to evaluate the effect of GPIIb/IIIa antagonists. The manufacturer's normal range for ADP high-sensitivity test with hirudin anticoagulated samples is 43-100 U, for AA-test 71-115 U and for TRAP-test 84-128 U.
Study II
Timing and method of blood sampling was the same in Study II as in Study I. For the ex vivo model of platelet transfusion, hirudin anticoagulated whole blood samples (1.75 ml) were supplemented with allogenic ABO-compatible apheresis platelet concentrate from the hospital blood bank; the mean age of platelet concentrate was 1.6 ±0.9 days (range 0-5 days). Platelet concentrate was administered ex vivo in two doses (125 and 250 ll of platelet concentrate standardized to 1200
, ratio of noninhibited to inhibited platelets 1:2 and 1:1, respectively), to simulate platelet transfusion without risk for the patients. To maintain the volume of the additive regardless of dose, the lower dose of platelet concentrate was diluted with phosphate-buffered saline solution. The samples were then analysed with MEA using the same activators as previously described for Study I. The doses of platelet concentrate used were chosen to correspond to $2 and 4 units of apheresis platelets given to a 70-kg patient, because a patient who bleeds after cardiac surgery often needs more than one transfusion of platelets. At our institution, 1 unit of platelet concentrate consists of either $200 ml apheresis platelets from one platelet donor, or $320 ml platelets from four regular blood donors.
Platelets were collected with the Trima Accel system version 6.0 (Terumo BCT, Lakewood, CO, USA) according to the manufacturer's instructions and following national and European guidelines. Before the donation, the platelet count of the donor was at least 230 Â10 9 l -1 . Platelets were collected in autologous plasma, with a target concentration of 1600 Â10 9 l -1 for each donation. The whole blood to citrate ratio was 10:1. 
RESULTS
Study I
ADP-induced platelet aggregation gradually increased after discontinuation of ticagrelor (P < 0.001, Fig. 1 ), from 10 ±7.5 U at 12 h, and reaching a mean level of 55 ±31 U 96 h after discontinuation of ticagrelor ( Fig. 1 and Table 2 ). There was a large degree of interindividual variability in recovery of platelet function at all sampling times after discontinuation of ticagrelor: range 0-24 U at 12 h, 3-34 U at 24 h, 4-75 U at 48 h, 4-88 U at 72 h and 11-114 U at 96 h ( Fig. 2 and Table 2 ). The proportion of patients below the previously suggested cut-off level for operating without increased bleeding risk (22 U) was 94% at 12 h, 88% at 24 h, 48% at 48 h, 25% at 72 h and 25% at 96 h. Also AA-induced platelet aggregation significantly increased with time, but at a low level, from mean 10 ± 8 U at 12 h to 17 ± 9 U at 96 h (P = 0.003, Fig. 1 and Table 2 ). TRAP-induced platelet aggregation increased from mean 86 ± 17 U at 12 h to 112 ± 31 U at 96 h (P < 0.001, Fig. 1 and Table 2 ).
Study II
Ex vivo supplementation with platelet concentrate did not significantly increase ADP-induced platelet aggregation after discontinuation with either the higher or the lower dose ( Table 2 ). There was no difference between the lower and the higher dose of platelet concentrate (P = 0.98), but a minor interaction between time and dose for both the lower and the higher dose, with less effect at later timepoints [-0.14 U per hour Â dose for the lower dose (P = 0.041) and -0.15 U per hour and dose for the higher dose (P = 0.031)].
In contrast, AA-induced platelet aggregation was significantly increased when platelet concentrate was added (Table 2) . It increased to levels close to the normal range (71-115 U) for the lower dose of platelet concentrate, and to levels within the normal range for the higher dose at all times, independently of the level before supplementation. The greater effect of the higher dose with an increase of 21 U with the higher dose compared with the lower was statistically significant (P = 0.0013) in the mixed model. There was also a significant interaction between time and dose, with a slightly larger effect of transfusion at later timepoints [0.38 U per hour Â dose for the low dose (P < 0.001) and 0.27 U per hour Â dose for the higher dose (P = 0.004)].
TRAP-induced platelet aggregation was significantly increased after addition of the higher dose of platelet concentrate (11 U; P = 0.0058), but not with the lower dose (P = 0.59; Table 2 ). For the higher dose, there was an interaction between time and dose (-0.15 U per hour Â dose, P = 0.015) but not for the lower dose (P = 0.38).
DISCUSSION
The main findings of this study were the large interindividual variation in time to recovery of platelet function after ticagrelor discontinuation in ACS patients, and that ADP-induced platelet aggregation was not improved by ex vivo addition of platelet concentrate, independently of time since discontinuation.
Optimal timing of surgery in ACS patients treated with DAPT is based on adequate recovery of platelet function, without unwarranted delay after discontinuation, which could increase the risk of thromboembolic events. Today the timing is based on the clinical condition of the patient and the time since discontinuation of the P2Y 12 -inhibitor. A few studies, however, have demonstrated a correlation between results of platelet function tests and risk of major postoperative bleeding after cardiac surgery [15] [16] [17] . Current guidelines not only give some support to the use of platelet function test (Grade 2A recommendation, evidence level C) but also recommend discontinuation of ticagrelor at least 5 days before surgery [4] . This may be longer than necessary, as demonstrated by a recent large retrospective study that showed no significant increase in risk of major bleeding in ACS patients operated at 72-120 h compared with >120 h after discontinuation of ticagrelor [18] .
In Study I, we found that mean ADP-induced platelet aggregation increased as expected, gradually after discontinuation of ticagrelor, but with a large degree of interindividual variability. A slight increase in AA-and TRAP-induced aggregation was also observed, illustrating the partial dependence on P2Y 12 -signalling also in these responses [19] . The increase in AA-induced aggregation was only very minor, which can be explained by continuous treatment with aspirin throughout the study period.
This study supports the idea that, on average, 72 h of discontinuation allows adequate recovery of ADP-induced platelet function in most ticagrelor-treated patients. At 72 h, the mean ADP-induced aggregation was 38 U, which is above the suggested cut-off levels for increased bleeding risk of 22 U [15, 17] or 30 U [16] . Despite a relatively narrow range of aggregation at 12 h after discontinuation (0-24 U), the range increased with each subsequent time point. At 72 h, ADP induced aggregation ranged from 4 to 88 U, and 6 of 24 patients (25%) had an aggregation of <22 U, indicating an increased risk of major bleeding in these patients. With such a high degree of interindividual variability, these data suggest that if ticagrelor-treated patients are considered for surgery within 5 days after discontinuation, platelet function testing may be an important amendment in assessing the operative risk.
In Study II, platelet supplementation with clinically relevant doses resulted in little or no improvement in ADP-or TRAPinduced aggregation, but large increases in AA-induced aggregation at all timepoints after discontinuation. These findings are in line with previous studies comparing the effect of platelet concentrate after DAPT using ticagrelor [10] [11] [12] [13] , but this study expands the previous findings, showing no effect on ADP-induced aggregation even several days after discontinuation. The lack of effect of platelet concentrate may be explained by remaining ticagrelor-or its active metabolites-in the blood redistributing also to the transfused platelets. The negative interaction, however small, between time and platelet supplementation dose for ADP-test may reflect that platelets at later timepoints have recovered to more normal aggregability. As shown in our previous study [10] , platelet supplementation to blood samples from healthy controls does not improve platelet function induced by ADP. Another explanation could be that platelets in storage appear to be particularly vulnerable to desensitization of ADP-induced aggregation [20] .
Although this study and other studies have failed to demonstrate that platelets are an effective antidote to ticagrelor [10] [11] [12] [13] , our results should not be interpreted as though the use of platelet concentrate is futile in case of bleeding in patients with ongoing or recently discontinued DAPT with ticagrelor. Platelet concentrate would be expected to at least improve platelet aggregation by means of the COX-dependent pathway tested by AA, as demonstrated in this and other studies [10, 13] . Secondly, a recent clinical study demonstrated that there was a significant, albeit limited, effect of platelet transfusion in vivo on ADPinduced aggregation in ticagrelor-treated CABG patients [11] . This study has certain limitations, such as the limited study sample and its observational nature. The results are only applicable to the studied population, i.e. ticagrelor-treated ACS patients awaiting CABG. Perioperative haemostasis after cardiac surgery is a complex process, where platelet aggregability is only one piece of the puzzle. The ex vivo model of platelet function has inherent limitations, and does not take account of the influence of circulation or platelet interactions with endothelium or extravascular tissue. However, MEA has been shown to have a satisfactory correlation with the gold standard method (Born aggregometry) for assessment of platelet aggregation, with 80% sensitivity and 91% specificity [21, 22] , and is a point-of-care device that is easily adopted in clinical practice. Other more specific tests of P2Y 12 -inhibtion, e.g. the VASP assay, are more complicated and not possible to use bedside.
In conclusion, there is a large degree of interindividual variability in ADP-induced platelet aggregation after discontinuation of ticagrelor in patients awaiting CABG. This variability suggests an added benefit of preoperative platelet function testing in patients being considered for surgery after discontinuation of ticagrelor. Administration of platelet concentrate did not improve ADP-induced aggregation at any timepoint after discontinuation of ticagrelor.
